October 4, 2005 -- CancerVax and Serono stopped a Phase III trial of their cancer vaccine for melanoma, Angiotech Pharma signed a $42 million collaboration with CombinatoRx, Abbott Labs won two add-on indications for arthritis drug Humira, StemCells filed to sell up to $100 million in new stock, Centocor and Eli Lilly suspended enrolling patients in a Phase III trial of a stroke drug, and Adventrx Pharma in-licensed an oncology drug from privately held SD Pharmaceuticals. The Centient Biotech 200 held on to a small gain, closing 6 points higher at 3787, a rise of .16%. More details...
